Get the Stockscreener App
141.65
2.51%
-3.65
Illumina Inc stock is traded at $141.65, with a volume of 1.90M.
It is down -2.51% in the last 24 hours and up +7.67% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$145.30
Open:
$145.3
24h Volume:
1.90M
Relative Volume:
1.06
Market Cap:
$21.64B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
17.94
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+0.41%
1M Performance:
+7.67%
6M Performance:
+46.09%
1Y Performance:
+3.12%
1-Day Range:
$141.37
$145.42
1-Week Range:
$140.19
$151.00
52-Week Range:
$68.70
$151.34
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
141.65 | 22.20B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina, Inc.Common Stock (NQ: ILMN - FinancialContent
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
Oncology Research Solutions - Illumina
Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine
2026: A turning point for precision health - Illumina
Illumina's new connected multiomics platform set to boost its stock - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 54,987 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Nigeria
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Nigeria
Illumina Launches Billion Cell Atlas to Accelerate AI-Driven Drug Development - filmogaz.com
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - The Malaysian Reserve
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - morningstar.com
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance - MarketBeat
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - 富途牛牛
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Billion Cell Atlas to accelerate AI, drug discovery - BioWorld MedTech
Illumina Introduces Illumina Billion Cell Atlas To Accelerate AI Drug Discovery - Nasdaq
Illumina unveils dataset to speed up AI-powered drug discovery - Reuters
Illumina introduces billion cell atlas to accelerate AI and drug discovery - marketscreener.com
Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery - marketscreener.com
Illumina reports 5% revenue growth in Q4 2025, flat for full year By Investing.com - Investing.com India
Illumina Preliminary Q4, Annual Results Beat Analysts' View - Nasdaq
Illumina Reports Preliminary Fiscal Q4 Non-GAAP Earnings, Revenue - marketscreener.com
(ILMN) Illumina Expects 2025 Revenue About $4.34B, vs. FactSet Est of $4.28B - marketscreener.com
(ILMN) Illumina Expects Q4 Adjusted EPS Range $1.27 to $1.30, vs. FactSet Est of $1.21 - marketscreener.com
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView — Track All Markets
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
Assessing Illumina (ILMN) Valuation After New Multiomics Platform And Chief Medical Officer Appointment - Yahoo Finance
DNA Methylation Sequencing Market Set to Revolutionize - openPR.com
Illumina and PREMIA partner to expand clinical access to CGP in Asia - ANTARA News
Dr Eric Green named Illumina Chief Medical Officer - Medical Buyer
Illumina, Inc. (ILMN): A Closer Look At Its Growth Potential Amidst Analyst Ratings - DirectorsTalk Interviews
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 - marketscreener.com
Illumina names former NIH genomics director as chief medical officer - MedTech Dive
Illumina's New Connected Multiomics Platform Set to Boost Its Stock - The Globe and Mail
How Is The Market Feeling About Illumina Inc? - Benzinga
Hardman Johnston Global Advisors LLC Has $14.95 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
SG Americas Securities LLC Buys 53,795 Shares of Illumina, Inc. $ILMN - MarketBeat
Cerity Partners LLC Increases Stock Position in Illumina, Inc. $ILMN - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Illumina names former NIH official as medical chief; commercial chief joins Quanterix - Seeking Alpha
Former NIH genomics director Eric Green to join Illumina as CMO - statnews.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):